Figure 4 Time course of the development of physiological changes

Slides:



Advertisements
Similar presentations
Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Life expectancy at birth in all countries included
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 The US Centers for Disease Control and
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Carotid artery inflammation detected using 18F-FDG-PET
Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)
Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.
Nat. Rev. Neurol. doi: /nrneurol
Figure 4 Cerebrospinal fluid levels of neurofilament light chain
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Overview of risk factors for Parkinson disease dementia
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 The new concept of prodromal RBD
Figure 2 ER stress and proteostasis in neurodegenerative diseases
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Proportion of patients for whom NEDA
Figure 5 Number of AHSCT procedures for
Figure 1 Diagnostic tiers of Parkinson disease as single disease
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Translational research projects in LGMD
Nat. Rev. Neurol. doi: /nrneurol
Figure 6 Imaging methods used to study Parkinson disease
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Algorithm for immunosuppressive treatment
Figure 2 Precision medicine based on a network approach
Figure 1 Principles of therapeutic ultrasound
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Clinical correlates of neurodegeneration in MS
Figure 4 Flow chart of the MDS MSA Study Group aims
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Genetic pleiotropy in ALS
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Evolution of multiple sclerosis
Figure 1 The trajectory of cognitive ageing
Figure 4 Generation of tau seeds and spread of tau pathology
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Challenges for big data applications in cardiovascular care
Figure 2 Diagnostic scheme for MSA
Figure 3 Stroke-related deaths and DALYs by country development status
Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET
Figure 6 Combining population-wide and high-risk strategies
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Potential interplay between physiological
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Clinical aspects of LGMD subtypes
Figure 1 The VEGF family of growth factors
Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.
Figure 2 Pathophysiological mechanisms in LGMD
Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Timing of the effects of deep brain stimulation
Figure 1 A large number of genes are potentially associated with CIPN
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Rett syndrome severity and age at diagnosis by mutation type
Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Blood–brain barrier breakdown promotes neurodegeneration
Figure 2 A case of early-onset PSD
Figure 2 Network connections of the hypothalamus
Presentation transcript:

Figure 4 Time course of the development of physiological changes in relation to cognitive and motor changes in neurodegenerative syndromes Figure 4 | Time course of the development of physiological changes in relation to cognitive and motor changes in neurodegenerative syndromes. Physiological markers can develop presymptomatically and early in the disease course, thereby offering the potential to provide accurate, trackable biomarkers of disease. Further research is required to determine precisely when these changes arise in relation to cognitive and physical motor symptoms; the need to determine when changes arise is reflected by dashed lines. Ahmed, R. M. et al. (2018) Physiological changes in neurodegeneration — mechanistic insights and clinical utility Nat. Rev. Neurol. doi:10.1038/nrneurol.2018.23